PHVS NASDAQ
Pharvaris N.V.
1W: +6.6%
1M: +4.3%
3M: +18.1%
YTD: +43.6%
1Y: +63.5%
3Y: +81.0%
5Y: +95.6%
$38.02
+0.51 (+1.36%)
Weekly Expected Move ±5.2%
$34
$36
$38
$40
$42
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.7B
52W Range20.65-43.25
Volume1,447,544
Avg Volume563,801
Beta-2.32
Dividend—
Analyst Ratings
Company Info
CEOBerndt Modig
Employees148
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-04
Websitepharvaris.com
Grafenauweg 8
Zug, ZH 6300
CH
Zug, ZH 6300
CH
31 71 203 6410
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Latest News
Pharvaris rises on late-stage trial win for hereditary angioedema drug
At a glance: stocks gapping up premarket
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Legal & General Group Plc Buys New Stake in Pharvaris N.V. $PHVS
Pharvaris N.V. (NASDAQ:PHVS) Receives $51.08 Average PT from Brokerages
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Glassman Robert | M-Exempt | 8,000 | $20.00 | 2026-09-09 |
| Glassman Robert | S-Sale | 8,000 | $37.55 | 2026-09-09 |
| Glassman Robert | M-Exempt | 8,000 | $20.00 | 2026-09-09 |
| Lu Peng | S-Sale | 15,000 | $40.68 | 2026-09-08 |
| Modig Berndt | S-Sale | 2,292 | $34.77 | 2026-08-14 |